From Tier Table Database
CDC Office of Public Health Genomics (OPHG) conducts horizon scanning (a systematic research method to find and follow novel technologies appearing in the literature) to identify and track the progress of genomic tests as they move from research into clinical and public health practice. As an aid in organizing horizon scanning results, OPHG ranks genomic tests, and family health history applications, by levels of evidence. See detail.
| Disease/Disorder | Test or Application | Intended Use | Tier Classified | Detail |
|---|---|---|---|---|
| Personal or family history of breast cancer or ovarian cancer | Genetic counseling | Risk prediction for hereditary breast and ovarian cancer syndrome | Tier 1  | |
| Ovarian epithelial cancer (including fallopian tube cancer or primary peritoneal cancer) | Genetic counseling | Risk prediction for hereditary breast and ovarian cancer syndrome | Tier 1 | |
| Ovarian cancer | Next generation sequencing and analysis of BRCA1 and BRCA2 using FoundationFocus CDxBRCA Assay(TM) | Pharmacogenomic, to help in identification of ovarian cancer patients for whom rucaparib treatment is being considered | Tier 1 | |
| BRCA-related cancer; hereditary breast and ovarian cancer | Consideration of multigene BRCA1/BRCA2 testing, following specified test criteria, risk assessment and counseling* | Breast/ovarian cancer risk prediction | Tier 1 | |
| BRCA-related cancer; hereditary breast and ovarian cancer | Consideration of comprehensive BRCA1/BRCA2 testing of family member with greatest likelihood of mutation, following specified test criteria, risk assessment and counseling* | Breast/ovarian cancer risk prediction | Tier 1 |
.png)
No hay comentarios:
Publicar un comentario